Nuvectis Pharma, Inc. (NVCT)
| Market Cap | 719.07M +396.9% |
| Revenue (ttm) | n/a |
| Net Income | -50.45M |
| EPS | -2.03 |
| Shares Out | 34.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 258,702 |
| Open | 18.01 |
| Previous Close | 17.76 |
| Day's Range | 17.80 - 21.05 |
| 52-Week Range | 5.55 - 29.28 |
| Beta | -0.21 |
| Analysts | Strong Buy |
| Price Target | 35.40 (+69.3%) |
| Earnings Date | Nov 4, 2026 |
About NVCT
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is base... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for NVCT stock is "Strong Buy." The 12-month stock price target is $35.4, which is an increase of 69.30% from the latest price.
News
Nuvectis Pharma Earnings Call Transcript: Q3 2026
NXP100 gained China PNH approval, while NXP200 showed glioma responses and received China breakthrough designation. Q3 cash of $140 million supports expected operations into H2 2029 as multiple U.S. development milestones approach.
Nuvectis Pharma Earnings release: Q3 2026
Nuvectis Pharma released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Nuvectis Pharma Quarterly report: Q3 2026
Nuvectis Pharma has published its Q3 2026 quarterly earnings report on November 4, 2026.
Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights
In-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group transformed Nuvectis into a late-stage clinical development company. The...
Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026
Fort Lee, NJ, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative ...
Nuvectis Pharma Slides: Corporate presentation
Nuvectis Pharma has posted slides in relation to its latest quarterly earnings report, which was published on November 2, 2026.
Nuvectis Pharma’s NXP200 shows positive Phase 1b results in gliomas
Nuvectis announced positive, expanded data from the Phase 1b study for NXP200, a second-generation, paradox-breaker BRAF inhibitor, in patients with recurrent or progressive BRAF V600-mutated gliomas,...
Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas
Single-agent NXP200 was administered to 27 patients with recurrent or progressive gliomas (20 with high-grade and 7 with low-grade). The objective response rate (ORR) based on Response Assessment in N...
Nuvectis Pharma Slides: Corporate presentation
Nuvectis Pharma has posted slides in relation to its latest quarterly earnings report, which was published on October 14, 2026.
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-relate...
Nuvectis Pharma announces NXP200 granted BTD in China
Nuvectis Pharma (NVCT) announced that NXP200 has been granted Breakthrough Therapy Designation, BTD, for the treatment of patients with BRAF V600-mutant, recurrent or progressive high-grade glioma by ...
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
Fort Lee, NJ, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...
Nuvectis Pharma Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A recent in-licensing deal brought two promising compounds, including a once-daily oral factor B inhibitor with strong efficacy in PNH and IgAN, and a second-generation BRAF inhibitor for oncology. Robust funding supports clinical progress, with pivotal studies and key data readouts expected within the next year.
Nuvectis Pharma Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Leadership highlighted a robust pipeline with NXP100, a once-daily oral Factor B inhibitor, positioned for major PNH market entry and expansion into additional indications. Regulatory clarity, pivotal trial starts, and key data readouts are expected within the next 6–12 months.
Nuvectis Pharma Slides: Corporate presentation
Nuvectis Pharma has posted slides in relation to its latest quarterly earnings report, which was published on September 11, 2026.
Nuvectis Pharma To Participate in Upcoming Investor Conferences
Fort Lee, NJ, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...
Nuvectis Pharma initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Pete Stavropoulos initiated coverage of Nuvectis Pharma (NVCT) with an Overweight rating. Nuvectis’ NXP100 offers a potentially differentiated, once-daily oral Factor B inhib...
Nuvectis Pharma initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Pete Stavropoulos initiated coverage of Nuvectis Pharma (NVCT) with an Overweight rating.
Nuvectis Pharma files $200M mixed securities shelf
16:39 EDT Nuvectis Pharma (NVCT) files $200M mixed securities shelf
Nuvectis Pharma Registration statement: Registration filing
Nuvectis Pharma filed a registration statement on August 21, 2026, providing details about a securities offering with the SEC.
Nuvectis Pharma Slides: Corporate presentation
Nuvectis Pharma has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
Nuvectis Pharma price target raised to $34 from $22 at Lucid Capital
Lucid Capital analyst Christopher Liu raised the firm’s price target on Nuvectis Pharma (NVCT) to $34 from $22 and keeps a Buy rating on the shares post the Q2 report.
Nuvectis Pharma Earnings release: Q2 2026
Nuvectis Pharma released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Nuvectis Pharma Quarterly report: Q2 2026
Nuvectis Pharma has published its Q2 2026 quarterly earnings report on August 4, 2026.
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
FORT LEE, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovativ...